Health Canada is the Canadian federal authority for drug approvals, generic-equivalent assessments, and pharmacovigilance. The agency has been at the leading edge of generic peptide approvals because Canadian patent protection on key incretin molecules has lapsed earlier than in other G7 markets.
Canada became the first G7 country with an approved generic semaglutide on April 28, 2026 (Dr. Reddy's Laboratories), followed three days later on May 1 by a second approval (Apotex). Health Canada is now reviewing seven additional submissions, and Sandoz has signaled a Q3 2026 commercial launch. The agency has separately issued public safety advisories on unauthorized injectable peptides — including BPC-157, CJC-1295, and retatrutide — sold through online channels outside the regulated supply chain. US semaglutide patent protection runs through December 2031, making the Canadian market a multi-year preview of generic-pricing dynamics.
Stories here cover generic approvals, the Sandoz timeline, and safety advisories. See #generic-semaglutide, #patent-expiry, and #novo-nordisk.
Sandoz Group AG's preparations for a Q3 2026 Canadian commercial launch of generic semaglutide came into sharper focus over the weekend as Health Canada continues reviewing seven remaining generic submissions filed after the April 28 Dr. Reddy's and May 1 Apotex approvals. Sandoz signaled in late 2024 it would launch a Canadian generic semaglutide in 2026 when the active-drug patent expired; the company's filing is currently under Health Canada review with commercial readiness contingent on the agency's review timeline. Industry analysts expect Sandoz to enter the Canadian market with pricing 45-90% below the brand Ozempic CAD $300-400/month range, putting Sandoz generic pricing in the CAD $30-200/month tier (~$22-145 USD/month). The Canadian generic market is a five-year preview of what will hit the US after December 2031 patent expiry; watch what Ontario, BC, and Quebec formulary committees decide on listing terms over the next 90 days.
Health Canada announced May 1 approval of a second generic semaglutide injection, filed by Canadian-based Apotex as a generic version of Novo Nordisk's Ozempic. The April 28, 2026 first approval (Dr. Reddy's Laboratories) was followed three days later by the Apotex green light, making Canada the first G7 country with two approved generic semaglutide products. Health Canada is currently reviewing seven additional generic submissions. Patent context: Canadian patent protection lapsed earlier than expected after a Novo Nordisk maintenance-fee issue. Sandoz separately targets a Q3 2026 commercial launch and the company has projected 45-90% price reductions versus brand-name Ozempic. US patent protection runs through December 2031.
Health Canada warned Canadians against injecting unauthorized peptides purchased online, citing risks of organ damage and infection from products misleadingly labeled 'For Research Use Only.'
Health Canada issued a public advisory warning against unauthorized injectable peptide drugs sold online for weight loss, anti-aging, and bodybuilding. Seized products include BPC-157, CJC-1295, retatrutide, and others, with cited risks of liver/kidney damage, blood clots, and cancerous tumours.